Skip to content
OpenCapital
Get started

TG Therapeutics TGTX Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——

Other financials

Income statement

See full
Revenue$204.9M+69.6%
Gross profit$171.4M+62.8%
Operating income$34.8M+304%
Net income$19.8M+291%
EPS (diluted)$0.12+300%

Balance sheet

See full
Cash & equivalents$442.2M+235%
Total debt$753.6M+197%
Total equity$583.1M+146%
Total assets$1.5B+133%

Cash flow

See full
Operating cash flow-$17.9M+37.7%
CapEx$51.0K+104%
Free cash flow-$17.9M+37.6%

Valuation

See full
Market cap$8.15B-14.3%
Enterprise value$8.46B-11.1%
P/E17.6×-225×
P/S11.6×-13.0×

Profitability

See full
Gross margin83.1%-4.4pp
Operating margin21.3%+5.9pp
Net margin66%+55.8pp
FCF margin-6,328.4%+4,773pp

Returns & leverage

See full
Return on equity112.6%+92.9pp
Debt / equity1.3×+0.2×
Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's amortization expense related to capitalized debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TG Therapeutics's amortization expense related to capitalized debt issuance costs?
TG Therapeutics (TGTX) reported amortization expense related to capitalized debt issuance costs of $285K in Q1 2026.
How has TG Therapeutics's amortization expense related to capitalized debt issuance costs changed year-over-year?
TG Therapeutics's amortization expense related to capitalized debt issuance costs decreased by 6.3% year-over-year, from $304K to $285K.
What is the long-term trend for TG Therapeutics's amortization expense related to capitalized debt issuance costs?
Over 4 years (2021 to 2025), TG Therapeutics's amortization expense related to capitalized debt issuance costs has grown at a 1.4% compound annual growth rate (CAGR), from $1.15M to $1.22M.